Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 5, 2018

Study Completion Date

September 5, 2018

Conditions
Precocious Puberty, Central
Interventions
DRUG

Leuprolide Acetate 45 mg

Subcutaneous injection

Trial Locations (20)

1023

The Liggins Institute, University of Auckland, Auckland

32207

Nemours Children's Clinic, Jacksonville

32827

Nemours Children's Hospital, Orlando

33021

Joe DiMaggio Children's Hospital, Hollywood

34000

Instituto de Investigaciones Aplicadas a la Neurociencia, A.C., Durango

45229

Cincinnati Children's Hospital Medical Center, Endocrine, Cincinnati

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

55414

University of Minnesota, Minneapolis

64460

"Hospital Unversitario Dr. Jose Eleuterio Gonzalez", Monterrey

74135

University of Oklahoma College of Medicine, Tulsa

92123

University of California, San Diego, San Diego

98105

Seattle Children's, Seattle

98405

MultiCare Institute for Research and Innovation, Tacoma

1270001

Hospital Regional de Antofagasta Leonardo Guzman, Antofagasta

8330074

Pontificia Universidad Catolica de Chile, Santiago

8360160

Instituto de Investigaciones Materno Infantil (IDIMI), Santiago

C1425EFD

Hospital de Ninos, Buenos Aires

T3B 6A8

University of Calgary, Alberta Children's Hospital, Calgary

H4A 3J1

McGill University Health Centre, Montreal

G1V 4G2

CHU de Quebec-Universite Laval, Québec

All Listed Sponsors
lead

Tolmar Inc.

INDUSTRY

NCT02452931 - Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | Biotech Hunter | Biotech Hunter